Chronic Graft-versus-host Disease
Conditions
Keywords
Hematopoietic Stem Cell Transplantation, Chronic Graft-versus-host disease, Mesenchymal Stem Cells
Brief summary
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.
Detailed description
Allogeneic hematopoietic stem cell transplantation(allo-HSCT) can cure many hematologic diseases. Although great progress has been made in the prevention and treatment of side effects associated with transplantation,chronic graft-versus-host disease(cGVHD) remains an important complication that occurs in about 50% patients. The mortality of cGVHD and its complication could reach up to 50%,and cGVHD seriously influence the quality of life. At present, the first line treatment of cGVHD remains in discussion. Mesenchymal stem cells (MSCs) are a form of multipotent adult stem cells that can be isolated from bone marrow (BM), adipose tissue, and cord blood. Clinical applications of human MSCs are evolving rapidly with goals of improving hematopoietic engraftment, preventing and treating GVHD after allo-HSCT and so on. However, the efficacy of treatment of cGVHD remains undetermined. In the present study, the investigators will prospectively evaluate the efficacy and safety of ex-vivo-expanded MSCs in treating patients with cGVHD.
Interventions
BIOLOGICALMesenchymal stem cells
Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.
DRUGGlucocorticoids
Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.
DRUGcyclosporine
Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.
Sponsors
Sun Yat-sen University
Army Medical University, China
Peking University People's Hospital
Nanfang Hospital, Southern Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* A patient age of 18-65 years * Recipients of allogeneic hematopoietic stem cell transplantation Patients with moderate/ severe cGVHD without systemic treatment * Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
Exclusion criteria
* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * Primary disease relapse * Expected lifetime less than 3 months * Patients with any conditions not suitable for the trial (investigators' decision)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 12 weeks after the first dose of MSCs | Overall response rate （ORR）includes complete response (CR) and part response (PR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DFS | 1 year after the first dose of MSCs | Disease-free survival (DFS) |
| Response rate | 4 weeks after the first dose of MSCs | — |
| OS | 1 year after the first dose of MSCs | Overall survival (OS) |
| CMV DNA-emia | 1 year after the first dose of MSCs | CMV DNA-emia refers to detection of CMV DNA in peripheral blood via PCR. |
| PGF | 1 year after the first dose of MSCs | Poor graft function (PGF) refers to a slow or incomplete recovery of blood cell counts (ANC ≤0.5x10\^9/L and PLT ≤20x10\^9/L) by +28 days after allo-HSCT or a fall in blood cell counts to levels fulfilling the diagnostic criteria for PGF after successful and prompt hematopoietic engraftment. |
| EBV DNA-emia | 1 year after the first dose of MSCs | EBV DNA-emia refers to detection of EBV DNA in peripheral blood via PCR. |
Countries
China
Contacts
Primary ContactRen Lin, MD
Outcome results
None listed